This deliverable reports the interactions of the SIMCor consortium with regulatory stakeholders at this point (M18) of the SIMCor project. Those interactions were facilitated via a dedicated SIMCor Regulatory Advisory Board (RAB) meeting or via a continuous liaison between regulators and the in-silico community at large via the VPH partner. The outcomes of the discussions are reported here, and conclusions are derived for future actions and directions.

SIMCor (In-Silico testing and validation of Cardiovascular IMplantable devices) has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101017578.